VEP

Latham & Watkins Launches Virtual Experience Program on Capital Markets Law

Retrieved on: 
Tuesday, June 20, 2023
Learning, Veps, Competition law, IPO, Life, Capital market, Intellectual property, Queensland Recruiting Committee, Lawyer, VEP, Special, Competition, Forage, Public company, Mergers and acquisitions, Growth, Investment company, Female, Nursing, Security (finance)

NEW YORK, June 20, 2023 /PRNewswire/ -- Latham & Watkins LLP1 has launched the firm's newest Virtual Experience Program (VEP) on capital markets law. The free virtual program gives the business, academic, and legal communities the opportunity to represent the underwriters in an initial public offering (IPO), while learning about the nature of work at a global law firm. Participants will review corporate records, prepare an auditor "circle-up" on financial metrics, draft a principal stockholder table, and review a lock-up agreement in connection with an IPO.

Key Points: 
  • NEW YORK, June 20, 2023 /PRNewswire/ -- Latham & Watkins LLP1 has launched the firm's newest Virtual Experience Program (VEP) on capital markets law.
  • This program highlights the critical role capital markets lawyers play in supporting clients' growth and success, from IPO through their life as a public company.
  • The Capital Markets VEP launch marks Latham's eighth program on Forage, an innovative, open-access platform connecting users with companies and law firms.
  • To learn more about our Capital Markets Practice and careers at Latham, visit lwcareers.com.

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

Retrieved on: 
Friday, May 12, 2023
Health, General Health, Cognition, NCE, Rat, Cognitive deficit, Myelin, Therapy, Grey, Clinical trial, MD–MS program, Research, Biomarker, Multiple sclerosis, Remyelination, VEP, Trial of the century, MS, Regenerative medicine, Development, MRI, State Administrative Expenses, Magnetic resonance imaging, HIV disease progression rates, Patient, Administration, Frequency, Mouse, White matter, Visual acuity, Axon, Disease, Pharmaceutical industry, Medical imaging, Vaccine

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023.
  • Cash Position: As of March 31, 2023, Frequency had cash, cash equivalents and marketable securities of $66.7 million (excluding restricted cash), or $55.0 million net of debt.
  • Excluding stock-based compensation expense of $0.8 million, research and development expenses for the three months ended March 31, 2023 were $10.6 million.
  • Excluding stock-based compensation expense of $2.6 million, general and administrative expenses for the three months ended March 31, 2023 were $6.6 million.

VetsInTech Virtual Invasion 2023: The Conference That Connects Military Veterans with Top Tech Companies

Retrieved on: 
Thursday, March 16, 2023
Silicon, Stagwell, Education, Veteran, SAN, Spouse, VEP, Vet, Adobe, Employment, DEI, HR, Mentorship, Entrepreneurship, Cryptocurrency, Real estate

SAN FRANCISCO, March 16, 2023 /PRNewswire/ -- VetsInTech, the leading national non-profit dedicated to advancing career opportunities for veterans in the tech industry, announced its annual VetsInTech Virtual Invasion 2023 national conference. Scheduled to take place Friday, March 31, VetsInTech's Invasion 2023 conference assembles military veterans and military spouses from around the country for a day of panel discussions, workshops, and networking with recruiters and leaders from Silicon Valley's most innovative companies.

Key Points: 
  • SAN FRANCISCO, March 16, 2023 /PRNewswire/ -- VetsInTech, the leading national non-profit dedicated to advancing career opportunities for veterans in the tech industry, announced its annual VetsInTech Virtual Invasion 2023 national conference.
  • Invasion 2023 offers critical content to veterans and military spouses looking for an onramp into great careers in technology.
  • VetsInTech Invasion 2023 is spearheading its resources and extensive network to connect diverse veterans with top employers in the tech industry.
  • Invasion 2023 conference connects veterans with leading tech employers, helping to fill the critical gap in technology talent and providing a bridge for veterans to secure meaningful and rewarding careers.

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Retrieved on: 
Monday, March 13, 2023
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Massachusetts General Hospital, Multiple sclerosis, MS, Research, Neuron, OLE, Risk, Cerebrum, ALS, VEP, CNM, Sale, DTI, LS, Visual cortex, Community, MRI, White matter, Patient, Hospital, Food, Maryland Department of Commerce, Housing, FDA, SALT, Eye, Magnetic resonance imaging, Medical imaging, Cryptocurrency, Pharmaceutical industry

The initial placebo-controlled double-blinded Phase 2 RESCUE-ALS results were strengthened further with evidence of a survival benefit and preserved function at one year and beyond.

Key Points: 
  • The initial placebo-controlled double-blinded Phase 2 RESCUE-ALS results were strengthened further with evidence of a survival benefit and preserved function at one year and beyond.
  • In December 2022, Clene closed a debt facility with the Maryland Department of Housing and Community Development to borrow $5.0 million.
  • On March 3, 2023, Clene entered into common stock purchase agreement for up to $25.0 million with Lincoln Park Capital Fund, LLC.
  • Clene expects that its resources as of December 31, 2022, will be sufficient to fund its operations into the third quarter of 2023.

LyondellBasell Launches New Company Strategy

Retrieved on: 
Tuesday, March 14, 2023
Carbon, EO, ESG, Investment, VEP, Culture, EBITDA, Capital market, LyondellBasell, Growth, CLCS, Renewable energy, Sales, Management, Retail

LyondellBasell is positioning itself to be the company of choice for financial, environmental, social and governance (ESG) minded investors, customers and brand owners.

Key Points: 
  • LyondellBasell is positioning itself to be the company of choice for financial, environmental, social and governance (ESG) minded investors, customers and brand owners.
  • The new LyondellBasell strategy focuses on growing sustainable value and encompasses three key elements:
    Growing and upgrading the core: Growth will be focused on businesses where LyondellBasell has leading positions in expanding and well-positioned markets.
  • "Our products are an essential part of a safe, healthy and more sustainable living, and I am confident our new strategy will unlock the true potential of our company," said Peter Vanacker, LyondellBasell CEO.
  • While LyondellBasell intends to cease refining operations at its Houston Refinery, the company is evaluating future investments at the site.

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Friday, March 10, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, SNHL, Therapy, Trial of the century, Axon, MRI, Biomarker, Frequency, State Administrative Expenses, Sensorineural hearing loss, MD–MS program, MS, Multiple sclerosis, Patient, Regenerative medicine, Speech perception, Clinical trial, Administration, VEP, Myelin, Development, Magnetic resonance imaging, Remyelination, Pharmaceutical industry, Medical imaging, Cryptocurrency

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
  • MS in characterized by demyelination, stripping axons of the myelin sheaths that support neuronal signal conduction and axonal survival.
  • Net Loss: Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable period of 2021.
  • Net loss was $81.6 million for the full year ended December 31, 2022, as compared to $84.7 million for the comparable period of 2021.

Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System

Retrieved on: 
Monday, February 27, 2023
Safety, DMT, MD, Neuron, MHS, Research, Disease, Treatment, VEP, Great America Committee, FDA, Mitt, Patient, MRI, DTI, DMTS, Cerebrum, White matter, Multiple sclerosis, LS, Therapy, CNM, Eye, Visual cortex, SALT, Magnetic resonance imaging, MS, Sclerosis, Immunomodulation, COVID, Medical imaging, Gasoline, Fertilizer

The poster titled, “CNM-Au8 Phase 2 VISIONARY-MS Updated Trial Results,” contributes to the growing body of evidence supporting improvements in clinical neurologic function and significant paraclinical MRI and VEP findings.

Key Points: 
  • The poster titled, “CNM-Au8 Phase 2 VISIONARY-MS Updated Trial Results,” contributes to the growing body of evidence supporting improvements in clinical neurologic function and significant paraclinical MRI and VEP findings.
  • The VEP and MRI analyses presented were prespecified exploratory endpoints.
  • The updated multi-focal Visual Evoked Potential (mf-VEP) findings provide evidence of improved information transmission in the visual system (from the eye to the visual cortex) supported by statistically significant increases in amplitude.
  • These data help build a strong case in favor of pursuing CNM-Au8 in further Phase 3 studies.”

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Retrieved on: 
Monday, February 13, 2023
Health, Clinical Trials, Biomarker, Regenerative medicine, Meningitis, Therapy, MRI, Safety, Sensorineural hearing loss, VEP, Hearing loss, Patient, CSO, Clinical trial, Frequency, Interim, Magnetic resonance imaging, Speech perception, Myelin, MS, Remyelination, SNHL, Pharmaceutical industry

The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of an improvement in speech perception.

Key Points: 
  • The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of an improvement in speech perception.
  • Prior FX-322 studies had been designed to best understand patient etiologies and severities where a hearing signal could be observed.
  • The safety profile associated with FX-322 was favorable and no study participants experienced a serious adverse event that was associated with treatment.
  • Given these disappointing results, we will cease further development of the Company's drug candidates for hearing loss.

DATAMARK Selected by State of Idaho to Provide NG9-1-1 Software and Professional Consulting Services

Retrieved on: 
Tuesday, January 17, 2023
State, Public security, Data, Validation, PSAP, NENA, Next Generation 9-1-1, Partnership, VEP, Information system, Business development, Software, GIS, National Emergency Number Association, Software as a service, State of emergency, Business, Harriman State Park (Idaho)

SANTA ANA, Calif., Jan. 17, 2023 /PRNewswire/ -- DATAMARK, the public safety geographic information systems (GIS) team of Michael Baker International, announced today that the firm has been selected by the State of Idaho to provide Next Generation 9-1-1 (NG9-1-1) software and professional consulting services. The three-year contract will run through January 2026.

Key Points: 
  • SANTA ANA, Calif., Jan. 17, 2023 /PRNewswire/ -- DATAMARK , the public safety geographic information systems (GIS) team of Michael Baker International , announced today that the firm has been selected by the State of Idaho to provide Next Generation 9-1-1 (NG9-1-1) software and professional consulting services.
  • As part of the contract with the State of Idaho, DATAMARK will provide 43 PSAPs with access to DATAMARK VEP Editor for local GIS data maintenance and validations.
  • DATAMARK will also provide Professional Consulting Services to the State of Idaho to build a sustainable NG9-1-1 GIS plan, including workflows, policies and funding.
  • DATAMARK's VEP solution provides users with the ability to run validations as often as they need and supports complex implementation models.

Monterey County Emergency Communications Selects DATAMARK to provide Geospatial Data Management System

Retrieved on: 
Tuesday, October 4, 2022
Solution, GIS, Service, Water, Transport, Culture, Next Generation 9-1-1, LinkedIn, Business development, Industry, Legislation, Associate, Engineering, State of emergency, Twitter, Decision-making, Salt Lake Valley Emergency Communications Center, Architecture, EMS, Consultant, Partnership, Information system, Program, CTS, Leadership, Fujitsu Technology Solutions, VEP, Data management, NENA, Business, National Emergency Number Association, Population, Software as a service, Risk management, Facebook

SALINAS, Calif., Oct. 4, 2022 /PRNewswire/ -- DATAMARK, the public safety geographic information systems (GIS) team of Michael Baker International, has been selected by Monterey County Emergency Communications to provide validation software to support the Regional Geospatial Data Quality Control process.  As part of this contract, Monterey County will use DATAMARK's flexible and scalable validation tool, VEP (Validate-Edit-Provision), to perform regular quality control of GIS data used to support the county's dispatch system.

Key Points: 
  • SALINAS, Calif., Oct. 4, 2022 /PRNewswire/ -- DATAMARK , the public safety geographic information systems (GIS) team of Michael Baker International , has been selected by Monterey County Emergency Communications to provide validation software to support theRegional Geospatial Data Quality Control process.
  • As part of this contract, Monterey County will use DATAMARK's flexible and scalable validation tool, VEP (Validate-Edit-Provision), to perform regular quality control of GIS data used to support the county's dispatch system.
  • "We are already building on our partnership with Monterey County to deploy improved GIS data workflows that will set the standard for maintaining high-quality GIS for public safety."
  • DATAMARK's proven data remediation process leverages its cloud native VEP to ensure data meets National Emergency Number Association (NENA) standards.